Inhibition of NK cell-mediated ADCC with rituximab against CLL was observed in the NKG2A+ population (P < .001) and not the NKG2A− population (Fig. 2j and k), again indicating that the observed inhibition is through the HLA-E:NKG2A axis. The gene discussed is KLRC1; the disease is B-cell chronic lymphocytic leukemia.